About Retinal Degeneration Fund
Retinal Degeneration Fund is a company based in Raleigh (United States). It operates as a HealthTech. Retinal Degeneration Fund offers products and services including Investment in Retinal Therapies.
- Headquarter Raleigh, United States
- SectorsHealthcare
- Website retinaldegenerationfund.org
- Social LinkedIn
Products & Services of Retinal Degeneration Fund
Retinal Degeneration Fund offers a comprehensive portfolio of products and services, including Investment in Retinal Therapies.
Investments are made in retinal degeneration therapeutic companies.
Similar companies to Retinal Degeneration Fund
10 companies that operate in the same segment as Retinal Degeneration Fund (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Retinal Degeneration Fund
Retinal Degeneration Fund is headquartered in Raleigh, United States. It is registered at Raleigh, North Carolina, United States.
The Retinal Degeneration Fund is dedicated to accelerating life-changing outcomes for individuals with retinal degenerative diseases. Investments are made directly in therapeutic companies working on preventions, treatments, and cures for conditions such as retinitis pigmentosa, age-related macular degeneration, and Usher syndrome. The focus is placed on the healthcare sector, specifically ophthalmology, to address blinding conditions affecting over 200 million people worldwide. Support is provided through mission-related investments to drive research and development in this critical area.
Retinal Degeneration Fund offers Investment in Retinal Therapies.